November 14, 2023

The Honorable Charles Schumer Majority Leader US Senate S-221 Capitol Building Washington, DC 20510

The Honorable Mike Johnson Speaker of the House US House of Representatives H-232 Capitol Building Washington, DC 20515 The Honorable Mitch McConnell Minority Leader US Senate S-230 Capitol Building

Washington, DC 20510

The Honorable Hakeem Jeffries Minority Leader US House of Representatives H-204 Capitol Building Washington, DC 20515

Re: The Urgent Need to Reauthorize PAHPA

Dear Leaders Schumer and McConnell, Speaker Johnson, and Leader Jeffries,

On behalf of the undersigned organizations, we write to express our strong desire to see the Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorized before the end of the calendar year in the same bipartisan fashion it has been supported since the original authorization 17 years ago.

As you know, PAHPA underpins Department of Health and Human Services (HHS) agencies, programs, and funding authorizations for addressing national health security threats. PAHPA created the HHS Assistant Secretary for Preparedness and Response (now the Administration for Strategic Preparedness and Response) and the Biomedical Advanced Research and Development Authority (BARDA) and provides important congressional oversight and direction to federal programs related to early warning, prevention, preparedness, and response.

This overall framework expired on September 30, 2023, requiring stopgap, temporary extensions in the continuing resolution, which expires on November 17. We encourage Congress to include a comprehensive five-year PAHPA reauthorization in the next moving legislative vehicle.

The last three PAHPA bills all shared major recurring themes: they all adjusted to the changing threat landscape, focused on challenges identified since the prior bill, and considerably strengthened our nation's health security with each reauthorization.

Our nation's changing health security threat landscape and the federal government's responsibility to protect the American people demand that we work together now to find a strong bipartisan path forward to reauthorize this critical legislation. Whether the next health security threat is naturally occurring, the result of an accident, or intentionally caused, our country must be in a better position to prevent, prepare for, and respond to such incidents.

Failing to reauthorize PAHPA would have serious effects on our country's economic wellbeing, national security, and health security given the rapidly changing threat landscape.

We are hopeful that PAHPA will remain a strong bipartisan legislative framework, as it has always been. We stand ready to assist you in whatever ways we can to help get this important law reauthorized this year.

Sincerely (in alphabetical order),

BioForward Wisconsin 1Day Sooner

Acadian Ambulance Service, Inc. BioKansas

BioNJ Adaptive Phage Therapeutics

Aequor Inc. **Biotechnology Innovation Organization (BIO)**

American Ambulance Association **Bugworks**

America's Essential Hospitals Cencora

American College of Emergency Physicians Colorado BioScience Association

American College of Surgeons Council of State and Territorial

Epidemiologists American Hospital Association

Council of State Bioscience Associations American Lung Association

(CSBA)

Georgia Bio

Ginkgo Bioworks

American Pharmacies CSL Segirus

American Public Health Association Emergency Department Practice

Management Association American Society for Microbiology

Emergent BioSolutions Arizona Bioindustry Association, Inc. (AZBio)

Federation of American Scientists Association for Professionals in Infection

Control and Epidemiology

FluGen Inc.

Association of Maternal & Child Health

Programs

Gerontological Society of America Association of State and Territorial Health

Officials

Asthma and Allergy Foundation of America Global Health Investment Corporation

AstraZeneca Pharmaceuticals Global Health Technologies Coalition

ATCC (American Type Culture Collection) Gryphon Scientific

Atea Pharmaceuticals, Inc. **GSK**

Bavarian Nordic Health Industry Distributors Association

(HIDA) **Big Cities Health Coalition**

Healthcare Distribution Alliance BioCT

Healthcare Leadership Council Novavax

Healthcare Ready Ochsner Health

Helix Ohio Life Sciences Association

HIMSS (Healthcare Information and Oklahoma Bioscience Association

Management Systems Society)

PDS Biotechnology

HIV Medicine Association

PharmaJet Inc.

IAVI (International AIDS Vaccine Initiative)

Premier Inc.

Illinois Biotechnology Innovation
Organization
Public Health Accreditation Board

Infectious Diseases Society of America Research!America

INOVIO Pharmaceuticals SAB Biotherapeutics, Inc.

Institute for Progress Sanofi

Johns Hopkins Center for Health Security

SecureBio

Life Sciences PA Shionogi Inc.

Locus Biosciences SIGA Technologies, Inc.

Mallinckrodt Society for Public Health Education

Marked By Covid Soligenix, Inc.

MassBio Technologies for Pandemic Defense

McKesson Texas Healthcare & Bioscience Institute

Medical Alley Tonix Pharmaceuticals

Medical Countermeasures Coalition Trinity Health

Missouri Biotechnology Association (MOBIO)

TrippBio, Inc.

National Association of County and City Trust for America's Health

Health Officials United States Pharmacopeia (USP)

National Immigration Law Center University of Hawaii

New Mexico Biotechnology & Biomedical University of Maryland School of Medicine

Valneva USA

Association (NMBio)

New Orleans BioInnovation Center

NewYorkBIO

Virginia Biotechnology Association
NightHawk Biosciences

Vaxxas Inc

CC:

Chair Bernie Sanders Health, Education, Labor & Pensions Committee US Senate

Ranking Member Bill Cassidy Health, Education, Labor & Pensions Committee US Senate Chair Cathy McMorris Rodgers Energy & Commerce Committee US House of Representatives

Ranking Member Frank Pallone Energy & Commerce Committee US House of Representatives